Since STEAP1 has been associated with increased risk of prostate cancer relapse and with a high Gleason score,26,27 this has led to interest in using STEAP1 detection for monitoring metastatic disease28 as well as making it an attractive CAR target in metastatic prostate cancer. This evidence concerns the gene STEAP1 and Familial prostate cancer.